Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Miller, AA [1 ]
Case, D [1 ]
Atkins, J [1 ]
Giguere, J [1 ]
机构：
[1] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7132
引用
下载
收藏
页码：649S / 649S
页数：1
相关论文
共 50 条
  • [1] Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer
    Miller, Antonius A.
    Case, Doug
    Atkins, James N.
    Giguere, Jeffrey K.
    Bearden, James D.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) : 832 - 836
  • [2] A phase II and pharmacogenomic study of Irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC).
    Pillot, GA
    Hennenfent, K
    Read, W
    Marsh, S
    McLeod, HL
    Gao, F
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 648S - 648S
  • [3] Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer
    Takeda, K
    Takifuji, N
    Uejima, H
    Yoshimura, N
    Terakawa, K
    Negoro, S
    LUNG CANCER, 2002, 38 (03) : 303 - 308
  • [4] Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC): Updated results of an ongoing study.
    Read, WL
    Toles, L
    Romvari, E
    Adkins, D
    McLeod, H
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 707S - 707S
  • [5] Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer
    Jazieh, A. R.
    Komrokji, R.
    Gupta, A.
    Patil, S.
    Flora, D.
    Knapp, M.
    Issa, M.
    Karim, N. Abdel
    CANCER INVESTIGATION, 2009, 27 (09) : 932 - 936
  • [6] Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer
    Ichiki, M
    Rikimaru, T
    Gohara, R
    Koga, T
    Kawayama, T
    Matunami, M
    Oshita, Y
    Kamimura, T
    Aizawa, H
    ONCOLOGY, 2003, 64 (04) : 306 - 311
  • [7] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Flora, DB
    Kleykamp, B
    Knapp, M
    Shukla, R
    Jazieh, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 680S - 680S
  • [9] A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: Final report
    Pillot, Giancarlo A.
    Read, William L.
    Hennenfent, Kristin L.
    Marsh, Sharon
    Viswanathan, Avinash
    Cummings, Kristopher
    McLeod, Howard L.
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (09) : 972 - 978
  • [10] Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
    Kim, Hyeong Su
    Kim, Jung Han
    Kim, Byounghoon
    Choi, Hyun Chang
    Kwon, Jung Hye
    Choi, Dae Ro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1591 - 1597
12345